For research use only. Not for therapeutic Use.
Trelagliptin (Cat.No:I005205) is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes mellitus. It works by enhancing the action of incretin hormones, which regulate blood glucose levels. Trelagliptin’s once-weekly dosing offers convenience and may improve medication adherence for diabetic patients.
| Catalog Number | I005205 |
| CAS Number | 865759-25-7 |
| Synonyms | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile |
| Molecular Formula | C18H20FN5O2 |
| Purity | ≥95% |
| Target | Dipeptidyl Peptidase |
| Solubility | in DMSO > 10 mM |
| Storage | Store at -20°C |
| IUPAC Name | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile |
| InChI | InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1 |
| InChIKey | IWYJYHUNXVAVAA-OAHLLOKOSA-N |
| SMILES | CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCC[C@H](C3)N |
| Reference | <p style=/line-height:25px/> <br>[2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus <br>[3]. Long-term Study of SYR-472 <br>[4]. SYR-472 Open-label Study </p> |
